| Name | Title | Contact Details |
|---|
LA POSADA AT PARK CENTRE Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Green Valley, AZ. To find more information about LA POSADA AT PARK CENTRE Inc., please visit www.laposadagv.com
U V Iii Systems is a Bellingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.
Pediatric Nursing Certification Board is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.